cd22 biotin protein (Sino Biological)
Sino Biological is a verified supplier 
Sino Biological manufactures this product 
94
Structured Review
Sino Biological
cd22 biotin protein
Cd22 Biotin Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd22+biotin+protein/Human+Siglec-2+%2F+CD22+Protein+(His+Tag)%2C+Biotinylated/pm41741641-688-40-42
Average 94 stars, based on 3 article reviews
Cd22 Biotin Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd22+biotin+protein/Human+Siglec-2+%2F+CD22+Protein+(His+Tag)%2C+Biotinylated/pm41741641-688-40-42
Average 94 stars, based on 3 article reviews
cd22 biotin protein - by Bioz Stars,
2026-09
94/100 stars
Images
Related Articles
Cytometry:Article Title: OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours. Article Snippet: Chimeric antigen receptor (CAR)-natural killer (NK) cell therapies hold promise for solid tumours but remain limited because of poor tumour infiltration, persistence and resistance in the tumour microenvironment.. Here, to identify gain-of-function targets that enhance CAR-NK cell efficacy, we performed an unbiased in vivo CRISPR activation screen followed by a barcoded targeted in vivo open reading frame screen in primary human CAR-NK cells.. We identified and comprehensively validated OR7A10, a G protein-coupled receptor (GPCR), as the top candidate. Software:Article Title: OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours. Article Snippet: Chimeric antigen receptor (CAR)-natural killer (NK) cell therapies hold promise for solid tumours but remain limited because of poor tumour infiltration, persistence and resistance in the tumour microenvironment.. Here, to identify gain-of-function targets that enhance CAR-NK cell efficacy, we performed an unbiased in vivo CRISPR activation screen followed by a barcoded targeted in vivo open reading frame screen in primary human CAR-NK cells.. We identified and comprehensively validated OR7A10, a G protein-coupled receptor (GPCR), as the top candidate. Activity Assay:Article Title: OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours. Article Snippet: Chimeric antigen receptor (CAR)-natural killer (NK) cell therapies hold promise for solid tumours but remain limited because of poor tumour infiltration, persistence and resistance in the tumour microenvironment.. Here, to identify gain-of-function targets that enhance CAR-NK cell efficacy, we performed an unbiased in vivo CRISPR activation screen followed by a barcoded targeted in vivo open reading frame screen in primary human CAR-NK cells.. We identified and comprehensively validated OR7A10, a G protein-coupled receptor (GPCR), as the top candidate. Expressing:Article Title: OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours. Article Snippet: Chimeric antigen receptor (CAR)-natural killer (NK) cell therapies hold promise for solid tumours but remain limited because of poor tumour infiltration, persistence and resistance in the tumour microenvironment.. Here, to identify gain-of-function targets that enhance CAR-NK cell efficacy, we performed an unbiased in vivo CRISPR activation screen followed by a barcoded targeted in vivo open reading frame screen in primary human CAR-NK cells.. We identified and comprehensively validated OR7A10, a G protein-coupled receptor (GPCR), as the top candidate. Incubation:Article Title: OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours. Article Snippet: Chimeric antigen receptor (CAR)-natural killer (NK) cell therapies hold promise for solid tumours but remain limited because of poor tumour infiltration, persistence and resistance in the tumour microenvironment.. Here, to identify gain-of-function targets that enhance CAR-NK cell efficacy, we performed an unbiased in vivo CRISPR activation screen followed by a barcoded targeted in vivo open reading frame screen in primary human CAR-NK cells.. We identified and comprehensively validated OR7A10, a G protein-coupled receptor (GPCR), as the top candidate. |